Draft:Halia Therapeutics, Inc.

Draft article not currently submitted for review.

This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window.

To be accepted, a draft should:

Show the subject qualifies for a Wikipedia article by using multiple sources that meet four criteria. The sources should be (1) reliable (2) secondary (3) independent of the subject (4) talk about the subject in some depth. For some topics, there are alternative criteria.
Be written from a neutral point of view
Respect copyright and do not plagiarize. Do not copy-paste.

It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it.

Where to get help

If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.

How to improve a draft

Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia.
Help:Wikitext – how to use the markup
Help:Referencing for beginners – how to include references
Wikipedia:Article development – how to develop your article
Wikipedia:Writing better articles – how to improve your article
Wikipedia:Verifiability – make sure your article includes reliable third-party sources

You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article.

Improving your odds of a speedy review

To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.

Add tags to your draft

Editor resources

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL
Easy tools: Citation bot (help) | Advanced: Fix bare URLs

Last edited by Brianverhaaren (talk | contribs) 14 days ago. (Update)

Submit the draft for review!

Type: Private
Industry: Pharmaceutical, Healthcare
Headquarters: Lehi, UT, United States
Key people: David Bearss, Ph.D., President and Chief Executive Officer
Founded: 2017
Website: https://haliatx.com/

Halia Therapeutics ^[1] ^[2] is a privately-owned pharmaceutical company based in Lehi, Utah that focuses on treating inflammatory disorders by targeting inflammasome.^[3]

History[edit]

Halia Therapeutics was founded in 2017 ^[4] by David Bearss, Ph.D.,^[5] Jared Bearss, and Brigham Young University-Hawaii's 11th president John S. K. Kauwe III. The company focuses on therapies for inflammatory disorders and neurological diseases. David Bearss, Ph.D. serves as President and CEO of the company. In 2024, Halia Therapeutics won the Medical & Health Med Tech Award Utah Business Innovation award, and its CEO David Bearss was awarded the Governor’s Medal for Science and Technology the same year, for his involvement as a consultant to the Governor during the COVID-19 pandemic, serving on several boards within the state of Utah, and his involvement in establishing the research arm of the Huntsman Cancer Institute and the U2TAH Therapeutics Accelerator at the University of Utah. ^[6] ^[7]

Financing[edit]

Halia Therapeutics completed Series C funding raised $30M.^[8] Financing was led by Todd Pedersen, with continued funding from previous investors. ^[9] ^[10]

Indications and Programs[edit]

Inflammation has been linked to myriad medical conditions^[11]^[12]. Halia Therapeutics' products target inflammation-related indications, including neurological disorders and cancers.^[13]

Halia Therapeutics’ lead candidate, HT-6184, inhibits the inflammasome by blocking the interaction between NLRP3 and NEK7^[14]. HT-6184 has been shown to be well tolerated in Phase I study in healthy volunteer subjects^[15]. HT-6184 is currently being tested in Phase II trials for MDS and inflammatory pain.^[16]^[17] It additionally will be tested in a different formulation that can cross the blood-brain barrier, HT-6153, to treat inflammatory diseases of the eye.^[18]

Further therapies that inhibit inflammasome include HT-6258 which will be tested as a treatment for gastroenterology.^[19]

Halia Therapeutics’ additional programs that target the inflammasome include HT-6283 for Neuroinflammation, HT-6515 for Dermatology, and HT-6153 for Intervertebral Disk Disease.

Halia Therapeutics has also developed LRRK2 inhibitor that is currently being evaluated in two additional programs. These include, HT-4253, which will be tested to treat Alzheimer’s Disease, and HT-4403 for Parkinson’s Disease. ^[20] ^[21] ^[22]

Sources[edit]

References:

[1] "TradeandIndustrydev.com - UT: Halia Therapeutics Opens New HQ and Lab Facilities in Lehi, with Potential for Dozens of Jobs".

[2] "ContractPharma.com - Halia Therapeutics Opens New HQ in Lehi, UT".

[3] "longevity.technology - Halia Therapeutics CEO on moving into multiple Phase 2 trials for chronic inflammation and whether the company may have created a 'longevity drug.'".

[4] "UtahBusiness.com - How David J. Bearss co-founded Halia Therapeutics - 7 December 2023".

[5] "Biosphere Magazine 2023, page 22" (PDF).

[6] "UtahBusiness.com - Introducing the 2023 Innovation Awards honorees, 30 October 2023".

[7] "business.utah.gov - Recipients of the 2023 Utah Governor's Science Medals Announced, 31 March 2023".

[8] "ENDPOINTS News - Halia's $30M Series C; Windtree assesses 'strategic' options; LifeArc, Gates invest in Africa accelerator, 31 January 2024".

[9] "PR Newswire - Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics, 31 January 2024".

[10] "CFO Dive - Biotech CFOs sharpen financing tactics for lean times, 17 January 2023".

[11] "Cleveland Clinic, Inflammation".

[12] "Nature.com - Chronic inflammation in the etiology of disease across the life span, 05 December 2019".

[13] "Bioworld.com, Halia closes a $30M series C to develop inflammasome inhibitors, 31 January 2024".

[14] "Science Direct, HT-6184 Inhibits the Formation of the NLRP3 Inflammasome in Human Monocytic THP-1 Cells, 2 November 2023".

[15] "National Library of Medicine - clinicaltrials.gov, Study to Evaluate HT-6184 in Healthy Subjects, 28 August 2023".

[16] "ashpublications.org, The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML, 28 November 2023".

[17] "Pharmaceutical Technology, Halia plans two trials testing its anti-inflammatory lead candidate, 22 August 2023".

[18] "BioTuesdays.com - Halia targeting chronic inflammation to keep people healthier, living longer, 22 August 2023".

[19] "BioTuesdays.com - Halia targeting chronic inflammation to keep people healthier, living longer, 22 August 2023".

[20] "BioTuesdays.com - Halia targeting chronic inflammation to keep people healthier, living longer, 22 August 2023".

[21] "UtahBusiness.com - Here's how Halia Therapeutics aims to curb Alzheimer's—and more, 20 May 2022".

[22] "Pharmaceutical Technology - Halia targeting chronic inflammation to keep people healthier, living longer, 22 August 2023".

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]